Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

As specific inhibitors of the gastric proton pump, responsible for gastric acidification, K-competitive acid blockers (P-CABs) have recently been utilized in the clinical treatment of gastric acid-related diseases in Asia. However, as these compounds have been developed based on phenotypic screening, their detailed binding poses are unknown. We show crystal and cryo-EM structures of the gastric proton pump in complex with four different P-CABs, tegoprazan, soraprazan, PF-03716556 and revaprazan, at resolutions reaching 2.8 Å. The structures describe molecular details of their interactions and are supported by functional analyses of mutations and molecular dynamics simulations. We reveal that revaprazan has a novel binding mode in which its tetrahydroisoquinoline moiety binds deep in the cation transport conduit. The mechanism of action of these P-CABs can now be evaluated at the molecular level, which will facilitate the rational development and improvement of currently available P-CABs to provide better treatment of acid-related gastrointestinal diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.2c00338DOI Listing

Publication Analysis

Top Keywords

gastric proton
12
proton pump
12
acid blockers
8
gastric
5
structural basis
4
basis binding
4
binding potassium-competitive
4
potassium-competitive acid
4
blockers gastric
4
pump specific
4

Similar Publications

Background: The most common cause of acid-peptic diseases (APDs) is Helicobacter Pylori (H. pylori) infection. Conventionally, proton-pump inhibitors (PPIs) are used to manage hyperacidity and dyspepsia.

View Article and Find Full Text PDF

The long-term visualization of intracellular Fe dynamics and lysosomal activity is crucial for investigating the physiological roles and functions of lysosomes during the growth of organisms. The lysosome-targeted fluorescent probe (RBH-EdC), derived from rhodamine-nucleoside conjugates, demonstrates a sophisticated dual-activation design: one is Fe⁺ response, triggering spirolactam ring-opening to form xanthine structures, resulting in ≥ 1000-fold fluorescence enhancement with visible colorimetric transition (colorless→pink). Another is pH sensitivity, demonstrating protonation-dependent fluorescence amplification at the dC at site N3 (pK= 2.

View Article and Find Full Text PDF

SiO NP promotes allergic gastritis induced by degranulation of mouse MC9 cell through AQP4-mediated impairment of SIRT3-TFAM deacetylation and mitochondrial autophagy.

J Hazard Mater

September 2025

College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, PR China; Key Laboratory of the Provincial Education Department of Heilongjiang for Common Animal Disease Prevention and Treatment, College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, PR C

Silicon dioxide nanoparticles (SiO NPs) are a novel material with a wide range of applications whose cumulative effects in the body pose certain health risks. The types of gastric injuries caused by different-sized SiO NPs and their mechanisms, however, remain unclear. Based on this, we established a mouse subchronic exposure model (10 mg/kg/d, 21 consecutive days of tube-feeding) with different SiO NP sizes (50, 300, and 1000 nm) in conjunction with in vitro MC9 and BMMCs models (160 μg/mL exposure for 24 h) to explore the gastric injury mechanisms.

View Article and Find Full Text PDF

Background: The optimal duration for vonoprazan and amoxicillin dual therapy (VA-DT) remains unclear, and studies on gastric acid suppression of vonoprazan during eradication are still lacking.

Objective: This study conducted a multicenter, randomized controlled trial to compare the eradication efficacy between 10 and 14-day VA-DT, and to identify the dynamic changes of gastric pH during treatment.

Methods: This study included 418 naïve adult patients with Helicobacter pylori infection, who were randomly divided into 10 or 14-day VA-DT groups (vonoprazan 20 mg twice daily and amoxicillin 1000 mg thrice daily).

View Article and Find Full Text PDF

Ménétrier disease: A clinical review.

World J Gastroenterol

August 2025

Department of Gastroenterology, Unidade Local de Saúde Tâmega e Sousa, Penafiel 4560-136, Porto, Portugal.

Ménétrier disease (MD) is a rare gastric disorder characterized by hypertrophy of the gastric mucosa, resulting in giant gastric folds, excessive mucus secretion, and significant protein loss. It is most common in middle-aged males, although cases have also been reported in children. This condition, also known as hyperplastic hypersecretory gastropathy, primarily affects the fundus and body of the stomach, leading to protein-losing gastropathy due to increased mucosal permeability.

View Article and Find Full Text PDF